An interventional phase Ib study (NCT04242238, Table 2) evaluated the concurrent administration of DCC-3014 (i.e., CSF1R inhibitor) and avelumab (i.e., anti–PD-1 antibody) in patients with advanced high-grade sarcoma, to deplete immunosuppressive M2 macrophages. Here, CSF1R is linked to sarcoma.